心脉医疗最新一期业绩显示，截至2025一季报，公司营业总收入3.32亿元、同比减少7.23%，归属净利 润1.30亿元，同比减少29.66%，扣非净利润1.22亿元，同比减少31.27%，流动比率6.284、速动比率 5.773、资产负债率13.00%。 天眼查商业履历信息显示，上海微创心脉医疗科技(集团)股份有限公司，成立于2012年，位于上海市， 是一家以从事研究和试验发展为主的企业。企业注册资本12326.2117万人民币，实缴资本5397.8147万人 民币。公司法定代表人为朱清。 金融界消息 截至2025年8月5日收盘，心脉医疗（688016）报收于111.89元，下跌1.37%，换手率 1.82%，成交量2.24万手，成交金额2.52亿元。 资金流向方面，今日主力资金净流出2609.57万元，占比成交额10.38%。其中，超大单净流出1320.54万 元、占成交额5.25%，大单净流出1289.02万元、占成交额5.13%，中单净流出流入1229.43万元、占成交 额4.89%，小单净流入1380.14万元、占成交额5.49%。 通过天眼查大数据分析，上海微创心脉医疗科技(集团)股份有限公司共对外 ...

最新一期业绩显示，2025年一季报，公司实现营业收入3.32亿元，同比-7.23%；净利润1.30亿元，同 比-29.66%，销售毛利率69.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13心脉医疗30.8227.473.59137.92亿行业平均 54.2450.504.73115.46亿行业中值37.9236.662.7954.21亿1九安医疗10.9911.110.87185.40亿2英科医疗 15.6216.841.39246.81亿3新华医疗16.0314.861.31102.77亿4山东药玻16.0716.121.85152.03亿5振德医疗 16.4215.471.0459.61亿6奥美医疗16.7916.461.7360.67亿7康德莱17.8017.811.4738.35亿8九强生物 17.8316.582.1888.30亿9维力医疗18.0519.292.2742.32亿10奥泰生物18.2519.241.4758.21亿11鱼跃医疗 19.9119.532.69352.67亿12安图生物20.2419.322.60230.80亿 股东方面，截至2025年3月31日，心 ...

Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has experienced a stock price increase of 3.41% as of August 4, 2025, closing at 113.44 yuan, with a trading volume of 29,500 hands and a transaction amount of 328 million yuan [1] - The company reported a total operating revenue of 332 million yuan for Q1 2025, representing a year-on-year decrease of 7.23%, and a net profit attributable to shareholders of 130 million yuan, down 29.66% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 6.284 and a quick ratio of 5.773, while the debt-to-asset ratio stands at 13.00% [1] Group 2 - Xinmai Medical has made investments in 5 external companies and participated in 353 bidding projects, indicating active engagement in business development [2] - The company holds 41 trademark registrations and 202 patent filings, showcasing its focus on intellectual property [2] - Additionally, Xinmai Medical possesses 162 administrative licenses, reflecting its compliance and operational capabilities [2]

8月4日，心脉医疗今日收盘113.44元，上涨3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到31.25倍，总市值139.83亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入3.32亿元，同比-7.23%；净利润1.30亿元，同 比-29.66%，销售毛利率69.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13心脉医疗31.2527.853.64139.83亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16.4615.511.0559.74亿6奥美医疗16.5616.231.7059.84亿7康德莱17.8617.871.4838.48亿8九强生物 17.9416.682.2088.83亿9维力医疗18.0819.322.2742.38亿10奥泰生物18.1519.131.4757 ...

证券日报网讯8月4日晚间，心脉医疗发布公告称，2025年7月份，公司通过集中竞价交易方式已累计回 购公司A股股份137，330股，占公司总股本的比例为0.11%。 ...

Group 1 - As of August 4, 2025, the stock price of Xinmai Medical is 113.44 yuan, an increase of 3.74 yuan or 3.41% from the previous trading day [1] - On the same day, the trading volume was 29,521 hands, with a transaction amount of 328 million yuan [1] - Xinmai Medical primarily engages in the research, development, production, and sales of interventional medical devices for aorta and peripheral blood vessels [1] Group 2 - In Q1 2025, the company achieved operating revenue of 332 million yuan and a net profit of 130 million yuan [1] - As of July 31, 2025, Xinmai Medical has repurchased a total of 1.09 million shares, accounting for 0.89% of the total share capital, with a repurchase amount of 113 million yuan [1] - The repurchase price range was between 84.26 yuan/share and 119.82 yuan/share [1] Group 3 - On August 4, 2025, the net inflow of main funds was 29.44 million yuan, while the net outflow over the past five days was 24.67 million yuan [1]

重要内容提示： | 回购方案首次披露日（第二期） | 2024/10/30 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限（第二期） | 2024 年 10 月 10 | 28 | 日~2025 | 年 | 月 | 27 | 日 | | 预计回购金额（第二期） | 10,000万元~20,000万元 □减少注册资本 | | | | | | | | 回购用途 | √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数（第二期） | 1,091,171股 | | | | | | | | 累计已回购股数占总股本比例 | 0.89% | | | | | | | | （第二期） | | | | | | | | | 累计已回购金额（第二期） | 113,259,321.90元 | | | | | | | | 实际回购价格区间（第二期） | 84.26元/股~119.82元/股 | ...

格隆汇8月4日丨心脉医疗(688016.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式（第二期）已累计回购公司股份109.12万股，回购成交的最高价为119.82元/股，最低 价为84.26元/股，支付的资金总额为人民币1.13亿元（不含印花税、交易佣金等交易费用）。 ...

8月1日，沪深两融数据显示，心脉医疗获融资买入额0.31亿元，居两市第545位，当日融资偿还额0.29亿 元，净买入223.38万元。 最近三个交易日，30日-1日，心脉医疗分别获融资买入0.61亿元、0.59亿元、0.31亿元。 融券方面，当日融券卖出0.06万股，净卖出0.06万股。 来源：金融界 ...

7月30日，心脉医疗今日收盘111.61元，下跌2.09%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到30.75倍，总市值137.57亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，心脉医疗排 名第61位。 股东方面，截至2025年3月31日，心脉医疗股东户数18176户，较上次增加523户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13心脉医疗30.7527.403.58137.57亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿1九安医疗11.0711.200.87186.87亿2英科医疗 14.0715.171.25222.33亿3新华医疗15.9114.751.30101.98亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2116.261.86153.29亿6奥美医疗16.3215.991.6858.96亿7康德莱17.1917.201.4237.04亿8九强生物 17.5016.272. ...